Letter to the editor regarding

Singhania, Pankaj; Bhattacharjee, Rana

Singhania, Pankaj¹; Bhattacharjee, Rana¹

Letter to the editor regarding "Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial"

J Bone Miner Res. January 2022;37(1):167-168

Affiliations

¹Department of Endocrinology and Metabolism, IPGME&R and SSKM Hospital, Kolkata, India
Links

DOI: 10.1002/jbmr.4446

PubMed: 34542188

WoS: 000703736100001
History

Received: 2021-08-11

Accepted: 2021-09-02

Cited Works (2)

Year	Entry
2007	Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. May 3, 2007;356(18):1809-1822.
2021	Edwards WB, Haider IT, Simonian N, Barroso J, Schnitzer TJ. Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial. J Bone Miner Res. November 2021;36(11):2127-2138.